Thromb Haemost 1993; 69(05): 415-417
DOI: 10.1055/s-0038-1651625
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Lack of Association Between Antiphospholipid Antibodies and Migraine

D A Tsakiris
1   The Coagulation and Fibrinolysis Laboratory, University Hospital of Basel, Switzerland
,
L Kappos
2   Department of Neurology, University Hospital of Basel, Switzerland
,
G Reber
3   Haemostasis Unit, University Cantonal Hospital, Geneva, Switzerland
,
G A Marbet
1   The Coagulation and Fibrinolysis Laboratory, University Hospital of Basel, Switzerland
,
J Le Floch-Rohr
4   Department of Neurology, University Cantonal Hospital, Geneva, Switzerland
,
E Roux
5   Division of Rheumatology, University Cantonal Hospital, Geneva, Switzerland
,
P de Moerloose
3   Haemostasis Unit, University Cantonal Hospital, Geneva, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 12. Oktober 1992

Accepted after revision 21. Dezember 1992

Publikationsdatum:
25. Juli 2018 (online)

Summary

We prospectively studied the prevalence of lupus anticoagulant, anticardiolipin antibodies (aCL) and various haemostatic parameters in 71 patients with migraine and compared the results with a control group of 32 subjects with back pain never having experienced migraine. The patients with migraine were divided into two groups: group I with migraine without (n = 18) and with aura lasting less than 60 min (n = 24) and group II with migraine with prolonged aura or migrainous infarction (complicated migraine, n = 29). The following results were obtained: a) no difference in aCL positivity was noted between migrainous patients and controls and between common migraine and complicated migraine patients and b) no statistically significant difference in haemostatic parameters (except for thrombin-antithrombin III complexes) was found between the two groups of migraine and between aCL positive and negative migrainous patients. These data suggest that anticardiolipin antibodies are not involved in the pathogenesis of migraine complications.

 
  • References

  • 1 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
  • 2 Galli M, Comfurius P, Maasen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
  • 3 Mc Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-Glycoprotein I (Apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
  • 4 Tobelem G, Cariou R, Camez A. The lupus anticoagulant and its role in thrombosis. Blood Rev 1987; 1: 21-24
  • 5 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
  • 6 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107
  • 7 Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant -antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-Thrombomodulin. J Rheumatol 1990; 17: 785-789
  • 8 Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-698
  • 9 Levine SR, Welch KMA. The spectrum of neurological disease associated with antiphospholipid antibodies. Arch Neurol 1987; 44: 876-883
  • 10 Briley DP, Coull BM, Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25: 221-227
  • 11 Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol 1992; 239: 39-42
  • 12 Levine SR, Joseph R, D⁉Andrea G, Welch KM. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987; 7: 93-99
  • 13 Montalbán J, Cervera R, Font J. et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992; 42: 681-682
  • 14 Alarcon-Segovia D, Deleze M, Oria CV. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365
  • 15 Shuaib A, Barklay L, Lee MA, Suchowersky O. Migraine and antiphospholipid antibodies. Headache 1989; 29: 42-45
  • 16 Hogan MJ, Brunet DG, Ford DM, Lillicrap D. Lupus anticoagulant, antiphospholipid antibodies and migraine. Can J Neurol Sci 1988; 15: 420-425
  • 17 Hering R, Couturier EGM, Steiner TJ, Asherson RA, Clifford-Rose F. Anticardiolipin antibodies in migraine. Cephalalgia 1991; 11: 19-21
  • 18 Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-1196
  • 19 Montalbán J, Titus F, Ordi J, Barquinero J. Anticardiolipin antibodies and migraine-related strokes. Arch Neurol 1988; 45: 603 (Letter)
  • 20 Coull BM, Goodnight SH. Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 1990; 21: 1370-1374
  • 21 Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 07) 1-96
  • 22 Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-106
  • 23 Pelzer H, Schwartz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-159
  • 24 Triplett DA, Brandt J. Laboratory identification of the lupus anticoagulant. Br J Haematol 1989; 73: 139-142
  • 25 Thiagarajan P, Pengo V, Shapiro SS. The use of dilute Russel viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874
  • 26 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
  • 27 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural pattern. Br J Haematol 1978; 40: 143-151
  • 28 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
  • 29 Reber G, Tremblet C, Bernard C, Mermillod B, de Moerloose P. Buffer’s influence on the detection and quantitation of anticardiolipin measured by ELISA. Thromb Res 1990; 57: 215-226
  • 30 Blau JN. Migraine: theories of pathogenesis. Lancet 1992; 339: 1202-1207
  • 31 Olesen J, Edvinsson L. Migraine: a research field for the basic neurosciences. TINS 1991; 14: 3-5
  • 32 Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 1989; 42: 773-780
  • 33 de Moerloose P, Reber G, Vogel JJ. Anticardiolipin determination: Comparison of three ELISA assays. Clin Exp Rheumatol 1990; 8: 575-577